Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site Trial is 50% enrolled; six patients have received ATR12-351, a live precision dermatology therapeutic candidate Azitra presenting at the 2025 BIO International Convention BRANFORD, Conn. , June 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced encouraging safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting Netherton syndrome.» Mehr auf prnewswire.com
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
BRANFORD, Conn. , June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts.» Mehr auf prnewswire.com
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
BRANFORD, Conn. , May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held May 30-June 3, 2025 in Chicago.» Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −2,84 Mrd | 104.268,94% |
EBITDA | −2,87 Mrd | 109.689,58% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 3,78 Mio€ |
Anzahl Aktien | 17,23 Mio |
52 Wochen-Hoch/Tief | 10,23€ - 0,19€ |
Dividenden | Nein |
Beta | -1,78 |
KGV (PE Ratio) | 0,00 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,00 |
KUV (PS Ratio) | 0,59 |
Unternehmensprofil
Name | AZITRA INC. NEW Aktie |
CEO | Francisco D. Salva |
Mitarbeiter | 12 |
Assets entdecken
Shareholder von AZITRA INC. NEW Aktie investieren auch in folgende Assets